NCT01588535已完成2 期
Phase 2, Multicenter, Placebo-controlled, Double-masked, Randomized Study to Demonstrate Reliability and Validity of FAECC Scale (Modified FLACC) to Evaluate Relief of Pain in Subjects With Acute Otitis Media Aged >/=2 Months to <5 Years
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 14
- 主要终点
- Consistency of primary assessor and caregiver FAECC scores using Pearson's correlation coefficient
研究概览
简要总结
This study is to assess the reliability and validity of the FAECC scale to evaluate pain associated with acute otitis media in children aged 2 months to 5 years.
详细描述
to assess the reliability and validity of the FAECC pain scale tool in children aged 2 months to 5 years with acute otitis media given AR01 or placebo
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Months 至 4 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has age in the interval 2 months ≤ age < 5.00 years, signs and symptoms of AOM, and moderate to severe pain (current episode ≤ 2 weeks duration). Moderate to severe pain is defined as a score of > or = 4 (on a scale of 0 - 10) for the FAECC scale as assessed by the primary assessor.
- •The patient's parent/guardian must have read and signed the written informed consent prior to study participation.
- •The patient is normally active and otherwise judged to be in good health on the basis of medical history and limited physical examination.
排除标准
- •Patient has perforated tympanic membrane, history of a perforated tympanic membrane in the last 6 months, or if a perforated tympanic membrane could not be ruled out by speculum examination, impedance testing tympanometry, pneumatic otoscopy, or Valsalva maneuver. Patients who are subsequently diagnosed with a perforated membrane during treatment are to be discontinued immediately. Patients with tympanostomy tubes are not allowed.
- •Patient has acute or chronic otitis externa.
- •Patient has chronic otitis media (current episode ≥ 2 weeks).
- •Patient has seborrheic dermatitis involving the affected external ear canal or pinna.
- •Patient has received any otic topical or systemic antibiotic within 14 days prior to study entry (topical or systemic antibiotics for acne will be allowed on a chronic basis for subjects who have been on a stable dose for at least 14 days prior to entry).
- •Patient has received any topical drying agent or over-the-counter therapy for otitis media within 36 hours prior to enrollment.
- •Patient has fever ≤ 102.0 F (oral or equivalent).
- •Patient has known hypersensitivity to the study drug or similar compounds including any of the inactive ingredients.
- •Patient is receiving medication on a chronic basis for pain (including steroidal or non steroidal anti-inflammatory drugs) and has not been on a stable dose for at least 1 month prior to entry into the study.
- •Patient has clinically significant mental illness (to be determined by the Investigator).
- •Patient has been exposed to any investigational agent within 30 days prior to study entry.
- •Patient has been previously enrolled in this study.
- •Patient or caregiver (parent/guardian) has a condition the Investigator believes will interfere with the ability to provide consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk.
- •Patient has a glucose 6-phosphate dehydrogenase deficiency or is taking concomitant medications associated with methemoglobinemia (such as nitrates or nitrites; aniline dyes; or medications, including lidocaine, prilocaine, phenazopyridine hydrochloride [Pyridium], and others).
- •Patient demonstrates clinical signs of anemia. The absolute amount of deoxygenated or abnormal hemoglobin (rather than its percentage) is required for cyanosis to be clinically evident. Patients with moderate-to-severe anemia may not appear cyanotic, even with elevated percentages of deoxygenated or abnormal hemoglobin.
- •Patient has congenital (i.e., hereditary) methemoglobinemia.
- •Patient has a recent history of acute gastroenteritis within 14 days prior to study entry. An association between methemoglobinemia and acute gastroenteritis in infants has been noted in several studies and may be due to acidosis from stool bicarbonate loss impairing the already immature function of the methemoglobin reductase system in these young patients.
研究组 & 干预措施
benzocaine solution
Active Comparator
ear drops
干预措施: benzocaine (Drug)
Placebo
Placebo Comparator
ear drops
干预措施: placebo (Drug)
结局指标
主要结局
Consistency of primary assessor and caregiver FAECC scores using Pearson's correlation coefficient
时间窗: up to 120 minutes after first dose and Day 4
次要结局
- reduction in pain scores from predose to each post-dose time point(up to 120 minutes after each dose)
研究者
研究点 (14)
Loading locations...
相似试验
招募中
不适用
Validity and Reliability Study of the Pain Indicator Behavior Scale-Brain Damage (ESCID-DC)PainBrain InjuriesBehaviorNCT04898491Candelas Lopez Lopez300
已完成
2 期
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial CystitisCystitis, InterstitialNCT00601484Pfizer65
尚未招募
3 期
SAGE OF visco elastic substance-2% HYDROXYPROPYLMETHYLCELLULOSE IN TWO DIFFERENT EYELID SPECULUMS AND COMPARING THEM IN REDUCING OVERALL PAIN DURING CATARACT SURGERYCTRI/2023/04/051788Command Hospital Eastern Command Kolkata
招募中
不适用
Investigation of reported pain intensities and symptoms of stress in formerly ventilated internistic patients on intensive care unit – a prospective observational studyR52.0Acute painDRKS00021112Zentrum für Palliativmedizin, Uniklinik Köln100
已完成
2 期
Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic NeuropathyPainful Diabetic NeuropathyNCT00695565Arcion Therapeutics Inc180